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Lipid raftInhibition of de novo palmitate synthesis via fatty acid synthase (FASN) inhibition provides an unproven ap-
proach to cancer therapy with a strong biological rationale. FASN expression increases with tumor progression
and associates with chemoresistance, tumor metastasis, and diminished patient survival in numerous tumor
types. TVB-3166, an orally-available, reversible, potent, and selective FASN inhibitor induces apoptosis, inhibits
anchorage-independent cell growth under lipid-rich conditions, and inhibits in-vivo xenograft tumor growth.
Dose-dependent effects are observed between 20–200 nM TVB-3166, which agrees with the IC50 in biochemical
FASN and cellular palmitate synthesis assays. Mechanistic studies show that FASN inhibition disrupts lipid raft
architecture, inhibits biological pathways such as lipid biosynthesis, PI3K–AKT–mTOR and β-catenin signal
transduction, and inhibits expression of oncogenic effectors such as c-Myc; effects that are tumor-cell speciﬁc.
Our results demonstrate that FASN inhibition has anti-tumor activities in biologically diverse preclinical tumor
models and provide mechanistic and pharmacologic evidence that FASN inhibition presents a promising thera-
peutic strategy for treating a variety of cancers, including those expressing mutant K-Ras, ErbB2, c-Met, and
PTEN. The reported ﬁndings inform ongoing studies to link mechanisms of action with deﬁned tumor types
and advance the discovery of biomarkers supporting development of FASN inhibitors as cancer therapeutics.
Research in context: Fatty acid synthase (FASN) is a vital enzyme in tumor cell biology; the over-expression of
FASN is associatedwith diminished patient prognosis and resistance tomany cancer therapies. Our data demon-
strate that selective and potent FASN inhibition with TVB-3166 leads to selective death of tumor cells, without
signiﬁcant effect on normal cells, and inhibits in vivo xenograft tumor growth at well-tolerated doses. Candidate
biomarkers for selecting tumors highly sensitive to FASN inhibition are identiﬁed. These preclinical data provide
mechanistic and pharmacologic evidence that FASN inhibition presents a promising therapeutic strategy for
treating a variety of cancers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fatty acid synthase (FASN) is a homodimeric and multi-functional
enzyme that catalyzes the biosynthesis of palmitate in a NADPH-
dependent reaction (Maier et al., 2006). Normal cells in adult tissue
ubiquitously express low to moderate levels of FASN; however, thesetide phosphate; HUVEC, human
cancer; CRC, colorectal cancer;
al media; DMEM, Dulbecco's
S, liquid chromatography–mass
cein isothiocyanate.
A and RNA are not deﬁned.
. This is an open access article undercells, which primarily import lipids from the extracellular milieu, do
not have a strict requirement for FASN activity. This is demonstrated
in a variety of mouse models with tissue-speciﬁc knockout of FASN
expression that are characterized by the absence of an effect under
non-stress conditions (Chirala et al., 2003; Shearn et al., 2014). In con-
trast, tumor cells have an increased requirement for lipids in functions
such as membrane biosynthesis, protein modiﬁcation, and as signaling
molecules. Consequently, tumor cells are more dependent on de novo
palmitate synthesis catalyzed by FASN than normal cells (Menendez
and Lupu, 2007; Flavin et al., 2010). Accordingly, FASN is overexpressed
in many solid and hematopoietic tumors, including breast, ovarian,
prostate, colon, lung, and pancreatic (Ueda et al., 2010; Shah et al.,
2006; Zaytseva et al., 2012; Witkiewicz et al., 2008; Sebastiani et al.,
2006). Moreover, FASN tumor expression is increased in a stage-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Ueda et al., 2010; Tao et al., 2013; Nguyen et al., 2010; Notarnicola
et al., 2012; Witkiewicz et al., 2008; Zaytseva et al., 2012). This expres-
sion–prognosis relationship suggests that FASN plays an important role
in affecting tumor cell biology and therapeutic response across a wide
range of cancer types.
Alteration of energy and macromolecular biosynthetic metabolism
in tumor cells compared to non-tumor cells is well established and
known as theWarburg effect, in recognition of OttoWarburg's hypoth-
esis that extended from his observation that ascites tumor cells convert
the majority of their glucose carbon to lactose in oxygen-rich environ-
ments (Ward and Thompson, 2012). Tumor cell survival, growth, and
proliferation demand increased energy in the form of NADPH and in-
creased macromolecular biosynthesis of DNA, RNA, protein, and lipids.
Reprogramming of tumor cell mitochondrial metabolism to support
these requirements occurs directly through growth factor signaling
and the PI3K–AKT–mTOR pathway. AKT activation drives both glycolyt-
ic metabolism of glucose and mitochondrial metabolism that generates
acetyl-CoA, the biosynthetic precursor of fatty acids, cholesterol, and
isoprenoid synthesis. As a critical aspect of tumor cell metabolic
reprogramming, mTORC1 complex activation occurs via AKT signal
transduction. A central component of themTORC1 cell growth program
is stimulation of de novo lipogenesis via regulation of SREBP-mediated
FASN expression (Shackelford and Shaw, 2009; Lupu and Menendez,
2006). In the synthesis of fatty acids, FASN consumes NADPH, acetyl-
CoA, and malonyl-CoA. The consumption of these substrates as well as
the production of fatty acids contributes to the sustained altered
metabolic state that tumor cells require for growth and survival.
Palmitate and additional fatty acids derived from its function in
diverse, vital biological processes. Fatty acids serve as precursors for syn-
thesis of cellular lipids, as lipid bilayer constituents that affectmembrane
ﬂuidity and architecture, and as substrates for post-translational protein
modiﬁcation that affect protein localization and activity. Palmitate affects
membrane architecture at specialized plasma membrane microdomains
known as lipid rafts. Lipid rafts are localized regions that contain high
concentrations of lipids such as palmitate, cholesterol, and sphingosine,
and also are rich in lipid-modiﬁed membrane-associated proteins that
function in receiving, localizing, and transmitting cell growth signals
(Simons and Sampaio, 2011; Staubach and Hanisch, 2011). Depletion
of palmitate and other cellular lipids is expected to cause reorganization
of membrane architecture and disruption of lipid raft domains. Growth
factor and intracellular signal transduction require intricate membrane-
associated protein–protein interactions that are dependent upon lipid
raft architecture and protein lipidation. These lipid rafts facilitate the
co-localization of proteins that must associate to form functional signal-
ing complexes, and thereby regulate the efﬁciency of signal transduction
as rafts increase and decrease in number and size. By disruption ofmem-
brane structure, FASN inhibition may disable signal transduction net-
works and biological processes required for cell growth, proliferation,
and response to cellular stress. Activation of these pathways is a hallmark
of cancer, and enables FASN inhibition to affect multiple points within a
tumor cell that can produce anti-tumor activity.
FASN activity is intimately linked to receptor tyrosine kinase (RTK),
PI3K–AKT–mTORandMAPK signaling pathways, and activation of these
pathways is a hallmark of aggressively growing tumor cells. Activation
of the PI3K–AKT–mTOR pathway is among the most frequent aberra-
tions in human cancers, and occurs through numerous different genetic
lesions (Vivanco and Sawyers, 2002). The PI3K–AKT–mTOR pathway
controls many biological processes that include glucose uptake andme-
tabolism, protein synthesis, cell growth, and cell survival (Hollander
et al., 2011). FASN gene expression is activated downstream of the
PI3K–AKT–mTOR signal transduction pathway in response to cell
metabolism and growth signals, and is driven by SREBP-1, ZBTB7A,
and p53 family transcription factors (Van de Sande et al., 2005; Choi
et al., 2008). Increased FASN activity promotes the tumorigenic capacity
of cells via multiple mechanisms that include supporting enhancedmacromolecular biosynthesis and glucose metabolism, cell growth
and survival signal transduction, cellular stress response, and resistance
to chemotherapeutic agents. In tumor cells, the connection between
signal transduction pathways and FASN often becomes inextricably
linked. Tumors with activated RTKs such as ERBB2 provide an example;
whereby, the ERBB2–PI3K–AKT–FASN signaling axis results in contin-
ued stimulation of ErbB2 activity (Grunt et al., 2009). The inter-
dependence enables tumor cells of this type to be killed with either
ErbB2 or FASN inhibitors.
FASN inhibition using siRNAs and small molecules with varied
biochemical mechanisms and selectivity proﬁles have been shown
to inhibit Akt phosphorylation, induce tumor cell apoptosis, sensitize
chemotherapy-resistant tumor cells to drug activity, and inhibit
mouse xenograft tumor growth (Chuang et al., 2011; Kant et al.,
2012; Kridel, 2004; Puig et al., 2008, 2009; Tomek et al., 2011).
These activities of FASN inhibition have been reported in different
tumor cell types that overexpress FASN, including, breast, ovary,
prostate, and colorectal tumors. Despite the compelling support for
FASN as an oncology therapeutic target, to date no compounds have
progressed into clinical studies. Some compounds previously described
in the literature suffered from signiﬁcant pharmaceutical liabilities,
including off-target activities such as stimulation of fatty acid oxidation
that leads to signiﬁcant and rapid weight loss in animal model studies
and confounds interpretation of study results (Liu et al., 2010;
Menendez and Lupu, 2007; Flavin et al., 2010). In vitro studies have
shown that inhibition of Akt phosphorylation and induction of tumor
cell apoptosis occur when FASN inhibition is uncoupled from CPT1
stimulation (Puig et al., 2008); thus suggesting that selective FASN
inhibition can achieve the desired tumoricidal effects without induc-
ing the rapid weight loss associated with activation of fatty acid
oxidation. These and other observations have spurred the discovery
and development of ‘next generation’ FASN inhibitors with opti-
mized pharmacological properties and in vivo tolerability.
We report studies that characterize the anti-tumor activity of TVB-
3166, a highly selective, potent, reversible, and oral FASN inhibitor dis-
covered and developed by 3-V Biosciences. Using in vitro and in vivo
models of human cancer we ﬁnd that FASN inhibition has multiple
mechanisms of action that can operate in speciﬁc types of tumors to
cause tumor cell apoptosis. These mechanisms include inhibition of
signal transduction through the PI3K–AKT–mTOR and β-catenin path-
ways that regulate tumor cell growth and survival. Our studies provide
insights into how these pathways are affected by FASN inhibition and
guide the discovery of biomarkers to select tumors with the greatest
susceptibility to the tumoricidal effects of FASN inhibition. We also
demonstrate that oral dosing of TVB-3166modulates the target enzyme
in vivo, is well tolerated, and inhibits mouse xenograft tumor growth in
a dose-dependent manner.
2. Materials and Methods
2.1. Cell Lines and Antibodies
The cell lines used were obtained from ATCC and ECACC, except
for OVCAR-8 cells (Biotox Sciences) The following antibodies were
used: FASN (3180; Cell Signaling), pAKT-S473 (4060; Cell Signaling),
pRPS6-S240 and 244 (2215; Cell Signaling), PARP-cleaved (9541,
Cell Signaling), β-catenin (9582, Cell Signaling), pβ-catenin-S675
(4176, Cell Signaling), LRP6 (2560, Cell Signaling) pLRP6-S1490 (2568,
Cell Signaling), c-Myc (5605, Cell Signaling), α-tubulin (2125; Cell Sig-
naling), N-Ras (sc-519, Santa Cruz Biotechnology), and cholera-toxin
subunit-B (227040; EMD Millipore).
2.2. Palmitate Synthesis Assays
Cells were seeded into 96-well culture plates at a density of
30,000 cells per well. After an overnight incubation, media were
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1 mM 13C-acetate and TVB-3166 across a range of concentrations in
0.5% DMSO. After 18 h incubation, the cells were washed and sapon-
iﬁed with sodium hydroxide, neutralized, and prepared for LC–MS
bioanalytical analysis using an API4000 mass spectrometer in SRM
mode.
2.3. Viability Assays
Screening assays using 2 different drug concentrations of cell line
panelswere conducted at Biotox Sciences (SanDiego, CA) and extended
dose-response assays were conducted at 3-V Biosciences. For drug
treatment, tumor cell lines were plated in 96-well plates in growthme-
dium (DMEM containing 10% FBS and 1% L-glutamine). 24-h after cell
plating, DMEM growthmediumwas removed and AdvancedMEM con-
taining 1% charcoal-stripped FBS, 1% L-glutamine, and the diluted com-
pound was added to each well. The ﬁnal drug concentrations in assay
wells were 10,000, 3300, 1100, 370, 123, 41, 14, 5, and 0 nM. Cell viabil-
ity was measured 7 days after compound addition using the Cell Titer-
Glo assay (Promega). IC50 determination was performed using a non-
linear regression curve-ﬁtting algorithm: log (inhibitor) vs. response-
variable slope (four parameter) within Graph Pad Prism 6.0a.
2.4. Lipidomics Analysis
Tumor cell lines were plated in growth media. 24-h after cell
plating, the growth media were removed and a ﬁnal concentration of
either 0.01% DMSO or 200 nM TVB-3166 was added to each ﬂask con-
taining Advanced MEM supplemented with 1% Charcoal Stripped FBS
and 1% L-glutamine. Cells were treated for 24-h, 48-h, or 72-h. Cells
were collected and washed in DPBS. Quantitative analysis of lipids was
performed at Metabolon (Sacramento, CA and Durham, NC) using LC–
MS-based methods and proprietary software.
2.5. Flow Cytometry
Cells were seeded in growth media. One day after seeding, the
media was changed to the Advanced formulation treatment media.
Cells were treated with TVB-3166 for 24 to 96 h and harvested by
Accutase (Gibco, cat.# A11105), washed with cold PBS, and stained
for Annexin V staining (FITC Annexin V Apoptosis Detection Kit II; BD
Pharmingen cat. # 556570). Flow cytometry analysis was performed
at Stanford University's Shared FACS Facility using the LSRII.UV instru-
ment that was obtained by Stanford University using NIH S10 Shared
InstrumentGrant (S10RR027431-01). Datawere analyzed at 3-V Biosci-
ences using FlowJo software (Ashland, OR).
2.6. Western Blot Analysis
For Western blot analysis cells were seeded in growth media. One
day after cell seeding, growth media was replaced by Advanced formu-
lation treatmentmedia containing TVB-3166. Cells were incubatedwith
TVB-3166 for 96 h. For analysis of β-catenin pathwaymarkers following
stimulation of cells with Wnt3A, cells were incubated with TVB-3166
for 78 h followed by addition of recombinant hWnt3A at 200 ng/mL
(R&D; cat# 5036-WNP) for an additional 18 h. Whole cell lysates were
prepared by adding RIPA buffer (Cell Signaling, 9806) supplemented
with HALT phosphatase and protease inhibitor cocktail (Pierce,
78442). Proteins were separated using SDS-PAGE, transferred to nitro-
cellulose membranes, blocked, and incubated with primary antibodies
overnight at 4 °C. Following washes in TBST, blots were probed with
HRP-conjugated secondary antibodies (Cell Signaling). ECL prime
chemiluminescent substrate (GE healthcare, RPN2232) was added and
blots were developed using LAS-4000 imager (Fujiﬁlm). Quantitation
of protein bands was performed using Multigauge software (version
3.2, Fujiﬁlm).2.7. TCF Reporter Assay
Cells were transduced with the TCF-LEF Luciferase Cignal Lenti
Reporter construct (Qiagen, 336851 CLS) 72 h prior the signaling
experiment. Cells were seeded and one day later exposed overnight to
the lenti-viral particles together with Sure ENTRY reagent (Qiagen,
336921). After stable integration of the TCF-LEF reporter 2–3 days
later, cells were harvested and 5–10 × 103 cells per well were seeded
in 96-well white clear bottom plates in growth media. After one day,
media was changed to the Advanced formulation treatment media
containing TVB-3166. After 48 h, hWnt3A (R&D, 5036-WNP) was
added to A-549 cells at 200 ng/mL and cells were incubated further
for 8 h. In experimentswithCOLO-205 cells, hWnt3Awasnot added. Lu-
ciferase was assayed using Dual-Glo Luciferase Assay System (Promega,
E2940).
2.8. Immunoﬂuorescence
CALU-6 cells were seeded in growth media at 200 cells per chamber
in Permanox 4-chamber slides (Fisher Scientiﬁc, 1256521). The follow-
ing day, media was replaced with treatment media containing TVB-
3166 and cells were incubated for 95.5 h. Fluorescent staining of lipid
raft domainswas performedusing cholera toxin patchingmethod as de-
scribed (Janes et al., 1999, Abulrob et al., 2004). Fixation was performed
in 4% formaldehyde for 20 min on ice. Permeabilization was performed
in PBSwith 0.1% Triton X-100 for 10min at room temperature. Blocking
was performed in PBS with 1% BSA for 30 min at room temperature. N-
Ras antibody (Santa Cruz Biotechnology, sc-519) diluted 1:250 in PBS
with 0.1% BSA was added and incubated overnight at 4 °C. Anti-rabbit
Alexa-ﬂuor 594 antibody (Life Technologies, ab150076) diluted 1:500
in PBS with 0.1% BSAwas added and incubated for 1 h at room temper-
ature. After 4× PBS washes, slides were mounted with coverslips using
Prolong Gold Antifademountingmediumwith DAPI (Life Technologies,
P36935) and hardened overnight. Imaging was performed using a Zeiss
LSM510 confocal microscope.
2.9. Soft Agar Colony Growth Assays
4 × 104 cells per well (in a 12-well plate) were resuspended in a
42 °C mixture of 0.35% ultrapure agarose (Life Technologies,
12200036), IMDM growth medium, and compound. The cell mixture
was laid over a solidiﬁed base layer comprised of 0.6% bacteriological
agar (Sigma, A5306) and IMDMgrowthmediumand allowed to harden
at room temperature for 1 h. A feeder layer comprised of IMDM growth
medium and compound was poured on top of the hardened cell mix-
ture. The feeder layer was replaced every 7 days and the number of col-
onies was counted after 3–4 weeks using OpenCFU colony counting
software (http://opencfu.sourceforge).
2.10. Gene Expression Analysis
PANC-1 and 22Rv1 cells were seeded in growth media. The follow-
ing day, treatment media with DMSO alone or with TVB-3166 (0.1 or
1.0 μM) was added and cells were incubated for an additional 48
(22Rv1) or 72 h (PANC-1). All treatments were performed in triplicate.
For PANC-1 Affymetrix microarray studies (HG-U133 Plus 2.0), cells
were lysed using Qiazol (Qiagen, 79306) and processed using the
RNeasy microarray kit (Qiagen, 73304). For 22Rv1 RNA sequencing
studies, cells were lysed using RLT buffer supplemented with β-
mercaptoethanol and processed using the RNeasy mini kit (Qiagen,
74104). Microarray and RNAseq analysis was performed at Expression
Analysis (Durham, NC). Data analysis was performed at 3-V Biosciences
using Partek Genomics Suite software (St. Louis, MO). The PANC-1
Affymetrix gene expression data is available through the NCBI-GEO
database using the accession number GSE64337.
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Female BALB-c-nude mice were inoculated subcutaneously at the
right ﬂank with PANC-1 or OVCAR-8 tumor cells. TVB-3166 treatment
via oral gavage administration was initiated when the mean tumor
size reached approximately 150 mm3. Mice were assigned into treat-
ment groups (N = 10) using a randomized block design based upon
their tumor volumes. Tumor sizes were measured twice weekly in
two dimensions using a caliper, and the volumes were expressed in
mm3 using the formula: V = width2 × length × 0.5. The study was ter-
minated 6 h after the ﬁnal dose. Tumor growth inhibition (TGI)was cal-
culated as the percentage of tumor growth, relative to tumor size at the
start of treatment, in drug-treated groups compared to vehicle-treated
groups. The Mann–Whitney U test was used to assess statistical signiﬁ-
cance of the mean tumor size between the drug and vehicle-treated
groups. The in-life phase of the studies was conducted by Crown Biosci-
ences (Santa Clara, CA, U.S.A. and Beijing, China). The experimenters
were not blinded to group assignments.
2.12. Patient-derived Xenograft Studies
Female BALB-c-nude mice implanted unilaterally in the ﬂank region
with tumor fragments harvested from donor animals. When tumors
reached approximately 100–300 mm3, animals were matched by
tumor volume into the treatment and control groups and TVB-3166
dosing by oral gavage was initiated. Tumor dimensions were measured
twiceweekly by a digital caliper and data including individual andmean
estimated tumor volumes (mean TV ± SEM) recorded for each
group; tumor volume was calculated using the formula (1): TV =
width2 × length × 0.52. Tumor growth inhibition (TGI) was calculated
as the percentage of tumor growth, relative to tumor size at the start
of treatment, in drug-treated groups compared to vehicle-treated
groups. The in-life phase of the studies was conducted by Champions
Oncology (Baltimore, MD). The experimenters were not blinded to
group assignments.
2.13. Animal Work Statement
CrownBio IACUC follows the “Guide of Animal Care and Use” NRC
2011, the Chinese National Standard and Local government's regula-
tions as well as animal welfare assurance number (A5896-01TC and
A5895-01BJ). As an AAALAC accreditation facility, Crown Bioscience
IACUC agree to play a role as monitoring the animal activities to ensure
the laws and regulations beingwell implemented in our facility. SoBran
Inc.'s Institutional Animal Care and Use Committee has approved all
animal use protocols at Champions Oncology and ensures that all
protocols meet the guidelines described in the Guide for the Care and
Use of Laboratory Animals.
3. Results
3.1. TVB-3166 Reversibly Inhibits Fatty Acid Synthase
In order to evaluate the anti-tumor properties of pharmacolog-
ical FASN inhibition, we characterized the properties of TVB-3166
(Fig. 1A), which has a lower molecular weight and increased solubility
than previously reported orally available, reversible, potent, and selec-
tive FASN inhibitors discovered and developed by 3-V Biosciences
(Oslob et al., 2013). In particular, the physicochemical properties were
optimized by replacing the benzimidazole moiety with a more polar
pyrrazole group (Oslob et al., 2014). These changes improved both sys-
temic and tumor exposures. TVB-3166 inhibits the keto-reductase
enzymatic function of FASN. The activity and potency of this com-
pound were demonstrated by growing HeLa cells in the presence
of 13C-acetate for 18 h and observing dose dependent inhibition
of 13C-labeled-palmitate synthesis measured by lipid extractionand mass spectrometry analysis (Fig. 1A). Very similar results were ob-
tained using 13C-glucose in the place of 13C-acetate (data not shown).
The cellular palmitate synthesis IC50 of 0.060 μM aligns with the
in vitro FASN biochemical IC50 of 0.042 μM that measures the catalytic
activity of puriﬁed FASN. FASN inhibition by TVB-3166 is reversible;
this was demonstrated in a cell-based assay. HeLa cells were exposed
to TVB-3166 for 4 h, followed by removal of the drug and addition of
13C-acetate for 18 h. Palmitate synthesis was not inhibited under
these conditions compared to cells treated continuously with the
inhibitor. These data demonstrated potent and reversible cellular
FASN inhibition with TVB-3166.3.2. FASN Inhibition Causes Selective Death of Tumor Cells
Palmitate, the enzymatic product of FASN, is a critical fatty acid that
functions directly in many vital cellular processes and also serves as a
precursor for the biosynthesis of longer and shorter chain fatty acids
and lipids. In order to fully characterize the impact of TVB-3166 on a
number of different tumor and normal cell lines we ﬁrst established
media conditions that supported robust growth across an array of di-
verse cell types. Many different tumor cell lines including COLO-205
and HT-29 cells were cultured 7 days in either Advanced MEM supple-
mented with 1% charcoal-stripped FBS and 1% L-glutamine or RPMI
supplemented with 5–10% FBS and 1% L-glutamine. Cell growth and
proliferation were comparable in the Advanced media (1% FBS) and
RPMI (5–10% FBS) formulations (data not shown). Next, a TVB-3166
dose response evaluation demonstrated similar effects on cell viability
when cells were treated in Advanced (1% FBS) or RPMI media with 5%
FBS (less than 15% difference). Increasing the FBS content in RPMI to
10% resulted in a 20–50% reduction in sensitivity depending upon the
cell type (Fig. 1B). The basis for this reduction could be effects on the
cells or nonspeciﬁc protein binding of the drug. From these combined
data, it was determined that Advanced media containing 1% FBS sup-
ported robust cell growth that enabled the measurement of TVB-
3166-mediated cell killing. To demonstrate the overall suitability of Ad-
vancedmedia with 1% FBS for measuring the effects of TVB-3166 on cell
viability, COLO-205 cells were incubated continuously for 7 days in the
presence of TVB-3166 or had the media and drug replenished after
4 days of growth. The overall reduction of cell viability was similar
under both conditions; thus, indicating the effect on cell viability is
due to impact of the drug and not from cumulative nutrient andmetab-
olite alterations in the media. These data supported the use of the
Advanced media formulation and it was used throughout unless other-
wise stated.
The on-target effect of TVB-3166 was evaluated in cells by the
addition of exogenous palmitate. FASN inhibition using TVB-3166
caused cell death in CALU-6 non-small-cell lung tumor cells with a cel-
lular IC50 value of 0.10 μM. This is in agreementwith the concentrations
required to inhibit cellular palmitate synthesis (IC50 0.081 μM) and
FASN in an in vitro biochemical assay (0.042 μM). Supplementing the
cell growthmedia with 25 μMpalmitate ameliorated the tumor cell kill-
ing activity of TVB-3166, although potent inhibition of FASN still oc-
curred under these conditions. Lower, more physiologically relevant
concentrations of palmitate did not impact signiﬁcantly the ability of
FASN inhibition to induce tumor cell death in our in vitro assay. The
ability of supraphysiological levels of exogenously applied palmitate to
prevent the phenotypic consequences of FASN inhibition as well as
the similar IC50 values in cell-based and in vitro assays demonstrated
that TVB-3166-induced cell death is an on-target effect of FASN inhibi-
tion (Fig. 1C).
TVB-3166 mediated cell killing is restricted to tumor cells; not nor-
mal cells. Inhibition of FASN-catalyzed palmitate synthesis in MCF-10A
breast epithelial cells, MRC-5 lung ﬁbroblasts, and endothelial cells
(HUVEC) was indistinguishable from that observed in CALU-6 tumor
cells; however, the inhibition of palmitate synthesis in these cells failed
Fig. 1. FASN inhibition with TVB-3166 inhibits palmitate synthesis and tumor cell viability. (A) TVB-3166 chemical structure (left) and reversible dose response inhibition of palmitate
synthesis in HeLa-Ohio cells (right). (B) Effects on cell viability in varied medium and serum conditions as shown. (C) TVB-3166 inhibits palmitate synthesis (gray) and viability (red)
with the same dose response and IC50 values in CALU-6 tumor cells. In the presence of 25 μM exogenous palmitate (blue) tumor cell viability is not affected. MRC-5 ﬁbroblasts (right)
have the same palmitate synthesis IC50 value as CALU-6 tumor cells but without the effect on cell viability.
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levels was due to inhibition of cell proliferation.
FASN inhibition induces cell death in diverse tumor cell. A panel of
90 different tumor cell lines representing six solid tumor types and
hematopoietic tumors were assayed for cell viability following treat-
ment with 0.02 or 0.20 μM TVB-3166 for 7 days (Fig. 2A–B). Dose-
dependent induction of cell death was observed in all tumor cell lines;
however, the percentage of cell death varied from 72% in the CALU-6
NSCLC cell line to less than 10% in the NCI-H1975 NSCLC cell line
(Fig. 2 B). 14 of the 50 cell lines show greater than 50% cell death in
this assay; whereas, 10 cell lines showed less than 10% cell death.
Variability in sensitivity to FASN inhibition was found between celllines from different solid tumor types and also in tumor cell lines of he-
matopoietic origin, indicating that features determining sensitivity
occur across tumor types.
FASN expression levels did not correlate with sensitivity to FASN in-
hibition in our studies. We measured FASN mRNA and protein expres-
sion in many of the 50 cell lines and did not establish a correlation
between FASN expression and TVB-3166 sensitivity. To investigate
other possible markers of FASN sensitivity, the effect of TVB-3166 on
the relative quantities of 36 different lipid species wasmeasured in sev-
eral tumor cell lines and compared to the extent of cell killing that re-
sults from FASN inhibition. In this analysis, TVB-3166 treatment for
72 h signiﬁcantly decreased both palmitate and total saturated fatty
Fig. 2. FASN inhibition inhibits tumor cell viability and sensitivity associates with saturated fatty acid levels. (A and B) 90 tumor cell lines from solid and hematopoietic tumor types were
proﬁled for sensitivity to FASN inhibition with TVB-3166 in the Cell Titer Glo assay for cell viability. Cells were treated with 0.2 μMTVB-3166 for 7 days in AdvancedMEMmedia with 1%
charcoal-stripped FBS. (B) KRAS mutations associate with sensitivity in lung tumor cell lines. (C) TVB-3166 decreases the absolute levels of palmitate and saturated fatty acids in tumor
cells. Tumor cells with lower pre-inhibition levels of palmitate and saturated fatty acids have increased sensitivity to FASN inhibition with TVB-3166 in a cell viability assay.
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bition on polyunsaturated fatty acids. Tumor cell lines that had lower
levels of palmitate and total saturated fatty acids prior to FASN inhibitor
treatment had increased sensitivity to TVB-3166 in cell viability assays
(Fig. 2C). KRAS mutation is associated with altered tumor cell metabo-
lism, and analysis of 30 lung tumor cell lines, in which approximately
50% harbors a KRAS mutation, showed enrichment for mutant KRAS in
cell lines with increased sensitivity to FASN inhibition (p b 0.05)
(Fig. 2B). In contrast, an association of FASN inhibitor sensitivity with
KRAS mutation status was not observed in analysis of 29 colon tumor
cell lines.
3.3. FASN Inhibition Prevents Anchorage-Independent Tumor Cell Growth
To characterize the effects of FASN inhibition on tumor cell growth
and survival further, studies were performed to assess the effect of
FASN inhibition on soft agar colony growth under conditions of com-
plete media with 10% FBS. Several tumor cell lines, representing lung,
ovary, prostate, and colorectal tumors, were examined at 0.1 or 1.0 μM
TVB-3166. In each of the different tumor cells, dose dependent inhibi-
tion of colony growth was observed. At a lower dose of 0.1 μM TVB-
3166 the most prominent effect is reduced colony size; however, at a
concentration of 1.0 μM both colony size and number were inhibited.
Colony growth of COLO-205, CALU-6, and OVCAR-8 cells showed
heightened sensitivity to FASN inhibition compared to 22Rv1 cells
(Fig. 3A). Together the ATP and soft agar assay results demonstrate
that FASN inhibition interferes with cell growth, proliferation, and via-
bility under varying medium and serum conditions that include 1–10%
FBS.
3.4. FASN Inhibition Induces Tumor-Cell Apoptosis
To determine whether FASN inhibition causes tumor cell death by
apoptosis, tumor cells were exposed to TVB-3166 and evaluated by
both FACS analysis for Annexin V staining and Western blot analysis
for PARP expression. Following treatment of lung (CALU-6) or prostate
(22Rv1) tumor cells with TVB-3166, a 4–5 fold increase in Annexin V
staining was observed for TVB-3166 treated cells compared to vehicle,
respectively (Fig. 3B). In this analysis, the lower right quadrant with
high Annexin V and lowpropidium iodide staining showed signiﬁcantly
more cells than the upper right quadrant with high staining for both
markers. This proﬁle indicated that cells were undergoing active apo-
ptosis rather thandying via necrosis. Further demonstrating the apopto-
tic mechanism of cell death, cleaved-PARP expression was found to
increase across a range of tumor cell lines by a magnitude of approxi-
mately 2-fold (MDA-MB-468 cells) to 100-fold (22Rv1 cells) (Fig. 3B).
3.5. FASN Inhibition Disrupts Lipid Raft Architecture and Localization of
Membrane-associated Signaling Proteins
Having demonstrated that FASN inhibition inhibits tumor cell
growth and survival under varied growth conditions; it was of interest
to characterize the cellular mechanisms that contribute to these
activities including those acting directly on lipid components. We
examined the effect of FASN inhibition on lipid raft architecture and
palmitoylated protein localization. CALU-6 or COLO-205 tumor cells
were treated with TVB-3166 for 96 h, at which time lipid raft architec-
ture and palmitoylated protein localization were imaged by immuno-
ﬂuorescent confocal microscopy. Lipid rafts were imaged using FITC-
conjugated cholera-toxin subunit-B, which speciﬁcally binds to the
cell surface raft-associated protein ganglioside GM1. As an example of
palmitoylated protein localization, N-Ras localization was determined
using the Alexa-ﬂuor-conjugated antibody. FASN inhibition with TVB-
3166 signiﬁcantly disrupted lipid raft organization and membrane
localization of N-Ras in both tumor cell types. In vehicle-treated cells
lipid rafts were seen as a largely continuous ring around the cell withinfrequent spots of lower intensity staining. N-Ras showed similar
membrane-associated staining; however, was also found with lower
intensity and partially punctate staining in the cytoplasm. Fig. 4A–B
shows representative control and drug treated cells. Following FASN
inhibition by 96 h of treatment with TVB-3166, lipid raft staining of
the plasma membrane was discontinuous and overall had a lower in-
tensity than that observed in control cells; sporadic staining was ob-
served at irregular intervals. N-Ras staining also was altered following
FASN inhibition. The plasma–membrane-associated pattern was dis-
continuous and irregular like the lipid rafts and the cytoplasmic distri-
bution showed an increased number of regions without any staining.
In addition to a greater number of cytoplasmic regions lacking N-Ras
staining, these regions were larger following FASN inhibition than
those in vehicle-treated cells. The effects were dose dependent; treat-
ment with 0.1 μM TVB-3166 (near the FASN IC50) induced moderate
changes that were more pronounced at 1 μM TVB-3166. Similar effects
of FASN inhibition were observed in both the CALU-6 and COLO-205
tumor cells. Together the lipid raft and N-Ras immunoﬂuorescence
data show that FASN activity is required for normal lipid raft architec-
ture and localization of membrane-associated signaling proteins such
as N-Ras.
3.6. FASN Inhibition Blocks Signal Transduction Pathways that Regulate
Tumor Cell Proliferation and Survival
Many signal transduction complexes are associated with lipid
raft membrane microdomains. Disruption of lipid rafts and raft-
associated protein localization provides a potential mechanism for
FASN inhibition-mediated modulation of signal transduction. To inves-
tigate the possible consequences of tumor cell membrane remodeling
following FASN inhibition, effects on signal transduction pathways in-
volved with control of cell proliferation and survival were examined
in several tumor cell lines. Dose-dependent inhibition of the PI3K–
AKT–mTOR and β-catenin pathways was observed by Western blot
analysis following in vitro treatment of several tumor cell lines with
0.02, 0.2, or 2 μM TVB-3166. FASN inhibition with TVB-3166 resulted
in the inhibition of Akt (S743) and ribosomal protein S6 (S240 and
244) phosphorylation in cell lines from different tumor types, including
lung, colon, prostate, ovary, and breast. The relative inhibition of Akt
and S6 phosphorylation differed between some cell lines. Inhibition of
both Akt and S6 phosphorylation was observed frequently; examples
include CALU-6, COLO-205, and OVCAR-8. In some tumor cells;
however, inhibition of Akt or S6 phosphorylation was observed but
not both. The prostate tumor cell line 22Rv1 provides an example
where TVB-3166 treatment resulted in inhibition of S6 phosphoryla-
tion without effect on Akt (Fig. 4C). Many tumor cells lines were
investigated with the aim of identifying an association between
known genetic features and the Akt-S6 inhibition proﬁle. Additional
cell lines that were proﬁled include A-549, OVCAR-5, HT-29, MDA-
MB-231, MDA-MB-453, and MDA-MB-468. Inhibition of pAkt
(S473) was observed in each of these cell lines; whereas, inhibition
of pS6 (240 and 244) was observed in a subset. The data suggest
that tumor cells with mutations in RAS, BRAF, PTEN, or ERBB2 are
likely to show pAkt (S473) inhibition (Table 1). The strongest inhibi-
tion of pS6 (240 and 244) was observed in a PIK3CA-mutant cell line,
22Rv1.
FASN inhibition with TVB-3166 inhibits β-catenin pathway signal
transduction and transcriptional activity (Fig. 4D). Phosphorylation of
β-catenin on serine 675 is associated with β-catenin protein stability,
nuclear localization, and transcriptional activation. TVB-3166 treatment
results in dose-dependent inhibition ofβ-catenin S675 phosphorylation
and β-catenin protein expression levels in COLO-205 and A-549 tumor
cell lines (Fig. 4D); similar results were observed in the MDA-MB-468
and OVCAR-8 breast and ovarian tumor cell lines, respectively (data
not shown). To further investigate the mechanism and consequences
of β-catenin inhibition by TVB-3166, transcriptional activity was
815R. Ventura et al. / EBioMedicine 2 (2015) 808–824measured using the TCF-TOPFLASH reporter system, and protein ex-
pression of TCF-regulated genes such as c-Myc was measured by
Western blot analyses. Data from these readouts showed that FASNFig. 3. FASN inhibition inhibits and anchorage-independent growth in soft agar induces apoptos
IMDMplus 10% FBS. Cellswere plated in 0.35%ultrapure agarose over a solidiﬁedbase layer of 0.
tate) tumor cells. Cells were treated with TVB-3166 for 72 (22Rv1 cells) or 96 h (CALU-6 cells)
measured by ﬂow cytometry. Cleaved PAPR was detected by Western blot analysis.inhibition blocks β-catenin pathway activity at multiple levels:
phosphorylation and expression of the Wnt ligand co-receptor
LRP6 is inhibited, TCF transcriptional activity is lowered to basalis. (A) Soft agar colony growth assays. Cells were treatedwith TVB-3166 for 21–28 days in
6%bacteriological agar. (B) TVB-3166 induces apoptosis in CALU-6 (lung) and22Rv1 (pros-
in Advanced MEMmedia with 1% CF FBS. Annexin V and propidium iodide staining were
816 R. Ventura et al. / EBioMedicine 2 (2015) 808–824levels, and c-Myc protein expression is reduced by 50%. Inhibition of
AKT–mTOR and β-catenin pathway signal transduction by FASN in-
hibition with TVB-3166 was not observed in MRC5 lung ﬁbroblasts,Fig. 4. TVB-3166 inhibits lipid raft architecture and signal transduction of the AKT–mTOR andβ-
Ras in COLO-205 (A) and CALU-6 (B) tumor cell lines. (C)Western blot analysis of CALU6, COLO-
3166 for 96 h. (D) Inhibition of β-catenin pathway activity by FASN inhibition. COLO-205 and A
expression analysis (left) or 96 h forWestern blot analysis (right). COLO-205 cells have constit
18 h before treating with TVB-3166.demonstrating that tumor and ﬁbroblast cells have differential de-
pendence on FASN for regulation of these proliferation and survival
pathways.catenin pathways. In vitro immunoﬂuorescent staining of lipid rafts (cholera toxin) and N-
205, OVCAR-8, and 22Rv1 tumor cell lines. Cellswere treatedwith 0.02, 0.2, or 2.0 μMTVB-
549 cells were treated with 0.2 μM TVB-3166 for 48 h for TCF promoter-driven luciferase
utive pathway activity. Where indicated, cells were stimulated with 200 ng/mlWnt3A for
Table 1
TVB-3166 inhibits Akt and S6 phosphorylation in diverse tumor cell lines.
Tumor cell
line
Tissue of
origin
RAS, BRAF, PIK3CA,
PTEN, ERBB2
% inhibition
pAkt (S473)
% inhibition pS6
(S240/244)
CALU-6 Lung KRAS 40 0
A-549 Lung KRAS 40 40
MDA-MB-231 Breast KRAS, BRAF 2 20
MDA-MB-453 Breast PIK3CA, PTEN, ERBB2a 70 40
MDA-MB-468 Breast PTEN 60 0
COLO-205 Colorectal BRAF, APC 66 81
HT-29 Colorectal BRAF, APC 95 0
22RV1 Prostate PIK3CA 0 73
OVCAR-5 Ovary KRAS 77 50
OVCAR-8 Ovary ERBB2b 54 0
Mutations reported in the COSMIC database.
a Copy number gain.
b Activating mutation.
817R. Ventura et al. / EBioMedicine 2 (2015) 808–8243.7. FASN Inhibition Modulates Gene Expression of Tumor Cell Metabolism,
Proliferation, and Survival Pathways
The signiﬁcant changes that TVB-3166 exerts on membrane struc-
ture and signal transduction pathways, combined with the observation
that tumor cells undergo apoptosis in response to drug treatment,
caused us to evaluate of the impact of FASN inhibition on tumor cell
gene expression. PANC-1 or 22Rv1 tumor cells growing in vitro were
treatedwith 0.1 or 1 μMTVB-3166 and analyzed for changes in gene ex-
pression. Genome-wide analysis using microarray and RNA sequencing
technology platforms showed extensive, coordinated, dose-dependent
effects of FASN inhibition on the transcriptional activity of genes within
pathways controlling tumor cell metabolism, proliferation, and survival.
Genes with signiﬁcant changes in mRNA abundance were identiﬁed
using the statistical (p b 0.01) and fold change (N1.6-fold) criteria
(Fig. 5A; Supplemental Tables 1–2). Highly coordinated changes were
evident in this analysis; the expression levels of multiple genes within
a pathway were all coordinately increased or decreased. Pathwaymod-
ulation by the induction of concerted gene expression changes is a re-
markable feature of FASN inhibition. Examples of regulated pathways
include up-regulation of sterol biosynthesis, pyruvate, amino acid, and
glucose metabolism pathways and down-regulation of cell cycle, DNA
replication, DNA-repair, and mitosis pathways (Table 2). Additional
pathways with signiﬁcantly increased gene expression include P53 sig-
naling and apoptosis; whereas, the β-catenin, Notch, and the unfolded
protein response pathways are down-regulated. Highly similar changes
were found in both PANC-1 and 22Rv-1 cells (Fig. 5B). Many of the
genes showingmodulation in response to FASN inhibition are regulated
downstream of the AKT–mTOR pathway via SREBP, e.g., genes within
the sterol and lipid biosynthesis pathways (Fig. 5C), or the β-catenin
pathway, e.g., genes involved in control of cell cycle progression and
cell proliferation.
FASN inhibition-mediated effects on gene expression were mea-
sured using selected RT-PCR assays in additional tumor cell lines as
well as in non-transformed cell types, including ﬁbroblasts and endo-
thelial cells. Tumor cell lines such as the NSCLC-derived line CALU-6
showed modulation of gene expression similar to that observed in the
PANC-1 and 22Rv1 cells, with increased expression of CASP1, LPIN1,
and ELOVL6 (Fig. 5D). In contrast, expression of these genes was not
affected by FASN inhibition in MRC5 lung ﬁbroblast and HUVEC
endothelial cells.
3.8. Once-daily, Oral Dosing of TVB-3166 Inhibits Xenograft Tumor Growth
In vivo efﬁcacy of FASN inhibition on tumor growthwas investigated
in tumor cell line and patient-derived xenograft tumormodels. Dose re-
sponsive tumor growth inhibition was observed in multiple tumormodels (Figs. 6–7). In the PANC-1 tumor cell line xenograft (Fig. 6A),
once-daily, oral dosing of TVB-3166 at 100 mg/kg for 18 days resulted
in statistically signiﬁcant 57% tumor growth inhibition compared to ve-
hicle (p= 0.04). A once-daily dose of 30mg/kg TVB-3166 showed non-
signiﬁcant 19% tumor growth inhibition. Tumor growth inhibition was
associated with dose-dependent inhibition of Akt phosphorylation
(S473) and induction of FASN expression (Fig. 6C). Inhibition of Akt
phosphorylation in FASN inhibitor-treated tumors, relative to vehicle
treatment, was 53% and 0% in the 100 and 30 mg/kg treatment groups,
respectively. FASN protein expression was increased 5.4 fold and 4-fold
in the high and low dose groups, respectively. Pharmacokinetic analysis
of plasma and tumor samples collected 6 h post-dosing showed the con-
centration of TVB-3166 to be approximately 3-fold higher in plasma
than tumor. The 100 and 30 mg/kg groups had plasma and tumor con-
centrations of 7 and 2.9 μM, respectively. Following normalization for
free, non-protein-bound drug, the TVB-3166 plasma concentration in
the 100 mg/kg group at 6 h post-dosing was equivalent to the FASN
IC50. The overall PK of TVB-3166 in mice predicts that most of the
drug is cleared by 12 h after dosing. Bodyweight losswas not signiﬁcant
in the TVB-3166-treated mice and was similar to changes observed in
the vehicle-treated mice. Together, the results demonstrated that TVB-
3166 has excellent oral bioavailability andmanageable pharmacokinet-
ic properties, which resulted in well-tolerated dose-dependent inhibi-
tion of Akt phosphorylation and tumor growth.
Dose-dependent efﬁcacy in the OVCAR-8 ovarian tumor cell line xe-
nograft was observed following once daily dosing of TVB-3166 (Fig. 6B).
In the OVCAR-8 tumormodel, once daily, oral dosing of TVB-3166 at 30,
60, or 100 mg/kg resulted in signiﬁcant tumor growth inhibition com-
pared to vehicle treatment. Following 21 days of dosing, tumor growth
inhibition values were 46, 59, and 74% (p= 0.0052) compared to vehi-
cle, respectively for the 30, 60, and 100mg/kg dose groups. Bodyweight
losswas not signiﬁcant in the TVB-3166-treatedmice andwas similar to
changes observed in the vehicle-treated mice. These results demon-
strated that well-tolerated doses of TVB-3166 were associated with
tumor growth inhibition efﬁcacy in K-Ras-mutant (Panc-1) and
ErbB2-mutant (OVCAR-8) tumor xenografts.
FASN inhibitionwith TVB-3166 showed tumor growth inhibition ef-
ﬁcacy in patient-derived xenografts (Fig. 7). Once-daily, oral dosing of
TVB-3166 at 60 mg/kg was found to inhibit tumor growth compared
to vehicle at 87%, 50%, and 47% in the CTG-0165, CTG-0160, and CTG-
0743 tumormodels, respectively. Body weight changes were not signif-
icant in TVB-3166-treatedmice andwere similar to changes observed in
vehicle-treated mice. CTG-0743 expresses mutant K-Ras (G12S);
whereas, CTG-0165 and CTG-0160 are KRAS-wild-type tumors. All
three tumors have wild type alleles of EGFR; however, CTG-0160 har-
bors a c-METmutation. The CTG-0165 and CTG-0743 tumors are adeno-
carcinomas; whereas, CTG-0160 is a squamous cell carcinoma. These
data show that FASN inhibition is well tolerated and inhibits tumor
growth in genetically and histologically diverse patient-derived NSCLC
tumor models, including squamous cell and adenocarcinomas as well
as tumors with varied genetic proﬁles that include KRAS and c-MET
mutations.
4. Discussion
We describe the activity of a highly selective, potent, reversible, and
orally available small molecule FASN inhibitor that has not been de-
scribed previously and characterize the biological consequences of
FASN inhibition using in vitro and in vivo preclinical tumor models.
Our ﬁndings show that FASN inhibition selectively inhibits growth and
viability of tumor cells both in vitro and in vivo, while having minimal
effects on non-tumor cells such as ﬁbroblasts and endothelial cells,
and demonstrate that tumor cells have a unique dependence on FASN
function for survival that is not present in normal cells. The potency
and selectivity of TVB-3166 for FASN aswell as its reversiblemechanism
of action differentiates it from earlier FASN inhibitors such as C75,
Fig. 5. TVB-3166 modulates metabolic and growth-associated pathways in tumor cells. PANC-1 cells treated with TVB-3166 for 72 h were analyzed for gene expression changes using
Affymetrix HU133 Plus 2.0 microarrays. Analysis includes unsupervised hierarchical clustering (A) and pathway enrichment analysis (B). Prostate and pancreatic tumor cell lines have
similar changes: sterol biosynthesis pathway (top) and cell cycle pathway (bottom). 22Rv1 prostate tumor cells were treated with TVB-3166 for 48 h and gene expression changes
were determined using RNA sequencing (RNASeq-25, Illumina, Inc). (C) Heat map showing 22Rv1 gene expression changes in lipid and sterol biosynthesis pathway genes. (D) RT-PCR
validation of microarray and RNA sequencing data in PANC-1 and 22Rv1 cells and extension of results to CALU-6 and MRC5 cells.
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Table 2
Pathways with signiﬁcant gene expression modulation by TVB-3166.
Pathway namea Enrichment score Enrichment
p-value
Steroid biosynthesis 19.01 5.55E−09
Cell cycle 14.42 5.47E−07
Metabolic pathways 9.13 0.0001
DNA replication 8.65 0.0002
p53 signaling pathway 8.06 0.0003
One carbon pool by folate 7.95 0.0004
Terpenoid backbone biosynthesis 7.60 0.0005
Insulin signaling pathway 7.06 0.0009
Viral carcinogenesis 6.45 0.0016
Aminoacyl-tRNA biosynthesis 6.07 0.0023
HIF-1 signaling pathway 5.61 0.0037
NF-kappa B signaling pathway 5.24 0.0053
Pyruvate metabolism 4.77 0.0085
Glycine, serine and threonine metabolism 4.28 0.0138
Biosynthesis of unsaturated fatty acids 4.17 0.0155
Folate biosynthesis 4.16 0.0156
Glycolysis/gluconeogenesis 4.10 0.0166
Glutathione metabolism 4.08 0.0169
2-Oxocarboxylic acid metabolism 3.91 0.0200
Mismatch repair 3.78 0.0228
Propanoate metabolism 3.65 0.0261
Dorso-ventral axis formation 3.61 0.0271
Selenocompound metabolism 3.47 0.0311
Pyrimidine metabolism 3.39 0.0336
Gap junction 2.98 0.0506
Mineral absorption 2.76 0.0632
Vitamin B6 metabolism 2.73 0.0655
Fatty acid biosynthesis 2.73 0.0655
a KEGG database.
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Our data show TVB-3166 to be well tolerated and to exhibit potent
and broad antitumor activity in diverse preclinical xenograft tumor
models.
FASN inhibition by TVB-3166 inhibits tumor growth and induces
tumor cell apoptosis via multiple mechanisms of action. This may ac-
count in part for the ﬁnding in our data and of others (Benjamin et al.,
in press) that FASN expression alone does not predict sensitivity to
FASN inhibition. Additional factors that likely contribute to the discon-
nect between FASN expression and sensitivity to FASN inhibition in-
clude: (1) the presence of post-translational mechanisms for
regulating lipogenesis (e.g., ACC1 phosphorylation) in the face of FASN
overexpression; (2) the association of FASN overexpressionwith a vari-
ety of genetic alterations (e.g., RTK overexpression and PI3K mutation)
that promote tumor cell growth and survival through mechanism and
pathways that can act in concert with or independent of FASN. Thus, a
combination of factors likely governs cellular saturated fatty acid levels,
which were found to associate with sensitivity to FASN inhibition.
Using ﬂow cytometry to measure Annexin V staining and Western
blot analyses to measure the expression of cleaved PARP, we show
that FASN inhibition induces apoptosis in many different tumor cell
lines. To investigate the mechanism of apoptosis induction, we charac-
terized the effects of FASN inhibition on lipid raft organization, cellular
localization of palmitoylated proteins, signal transduction activity
through pathways that regulate tumor cell proliferation and viability,
and whole-genome gene expression analysis. Our data reveal that
FASN inhibition disrupts lipid raft distribution in the plasmamembrane,
alters the localization of raft-associated proteins such as N-Ras, inhibits
multiple signal transduction pathways including PI3K–AKT–mTOR and
β-catenin, and modulates the expression of many genes in metabolic,
proliferation and apoptosis pathways. These ﬁndings are consistent
with a mechanistic model where FASN inhibition leads to the depletion
of palmitate and palmitate-derived lipids required for proper protein
trafﬁcking and localization and lipid raft organization and architecture.
Protein palmitoylation is required for trafﬁcking and localization of
many membrane-associated proteins, including all Ras and Wntisoforms (Ahearn et al., 2012; Song et al., 2013; Clevers and Nusse,
2012; Fiorentino et al., 2008). Mutant N-Ras that cannot be
palmitoylated localizes to intracellular membranes delimiting the
Golgi and shows impaired plasma membrane localization (Eisenberg
et al., 2011, 2013). The localization of N-Ras in our studies following
FASN inhibition showed this same pattern. Disruption of membrane
structure and lipid raft distribution results in impaired signaling by
preventing protein access to these critical lipid domains that bring com-
plex signaling machinery together at the appropriate subcellular loca-
tion. Lipid rafts are plasma membrane microdomains characterized by
high local concentrations of sphingolipids, glycolipids, sterols, and
lipid-modiﬁed proteins (Lingwood and Simons, 2010; Simons and
Sampaio, 2011). Additionally, raft domains are enriched for lipid species
with saturated and longer hydrocarbon fatty acid chains. Our data show
that palmitate and total saturated fatty acid levels are depleted by FASN
inhibition and, moreover, that tumor cell lines with lower levels of sat-
urated fatty acids exhibit increased sensitivity to FASN inhibition in via-
bility assays. Raft domains function as dynamic, organizing centers
within the plasma membrane and play a vital role in facilitating pro-
tein–protein interactions that promote mitotic and cell survival-
associated signal transduction. Thus, inhibition of de novo fatty acid
synthesis leads to the disruption of lipid raft architecture and organiza-
tion that is required for cell growth and survival signal transduction, and
this effect is expected to be greater in tumor cells than in resting or non-
tumor cells where lipid raft domains are smaller and less abundant. In
agreement with this model, the PI3K–AKT pathway, which is inhibited
in our studies by TVB-3166, has been shown to require lipid rafts for sig-
naling activity in multiple tumor cell lines (Reis-Sobreiro et al., 2013;
Lasserre et al., 2008).
Multiple signaling pathways that regulate tumor cell proliferation
and survival, including PI3K–AKT–mTOR and β-catenin, are inhibited
by FASN inhibition. Our data show that the effects on these pathways
vary between tumor cell lines and that particular cell lines are more
susceptible to inhibition of Akt, mTOR, or Wnt-β-catenin signaling.
We ﬁnd inhibition of the PI3K–AKT–mTOR and β-catenin pathways by
FASN inhibition in cell lines derived from a variety of tumor types, in-
cluding breast, colon, lung, prostate and ovarian tumors. Additional
work remains to identify strongly predictive markers of pathway sus-
ceptibility to FASN inhibition; however, our data suggest that Akt
(S473) inhibition is associated with RAS, BRAF, PTEN, or ERBB2 alter-
ations. Cell lines with activating PI3K mutations show mTOR inhibition
(as measured by phosphorylation of RPS6) and, less reliably, inhibition
of Akt. In an extended analysis of tumor cell lines for sensitivity to
FASN inhibition using an in vitro assay for cell viability, we ﬁnd that
KRAS and NRAS mutations associate with sensitivity to FASN inhibition
in non-small-cell lung cancer cell lines. Consistent with these data,
in vivo tumor growth inhibition was observed in a KRAS mutant
patient-derived NSCLC xenograft tumor. Highly sensitive colorectal
tumor cell lines included KRAS mutant lines but were not enriched for
such mutations, indicating that multiple factors inﬂuence FASN inhibi-
tor sensitivity. Taken together, our in vitro and in vivo data indicate
that FASN inhibition has potential utility in KRAS and NRAS mutant tu-
mors, and that this activity may be mediated, at least in part, by inhibi-
tion of AKT signaling.
FASN inhibition results in Wnt–β-catenin pathway inhibition
(Fiorentino et al., 2008), including decreased c-Myc expression, in cell
lines from a variety of tumor types, including colon, lung, breast and
ovarian tumors. Inhibition of the β-catenin pathway and c-Myc expres-
sion is a feature of FASN inhibition in cell lines with high constitutive
TCF promoter activity due to APC or β-catenin mutations, and also in
cell lines without thesemutations that increase promoter activity in re-
sponse to stimulationwith exogenousWnt3A. Our data show that FASN
inhibition blocks activation of the Wnt receptor and co-receptor com-
plex as we observe inhibition of co-receptor (LRP6) phosphorylation
in response to FASN inhibitor treatment, and further demonstrate that
FASN inhibition decreases β-catenin phosphorylation at serine 675
Fig. 6. TVB-3166 inhibits growth of cell-line-derived xenograft tumors. TVB-3166 was dosed once daily by oral gavage at 30, 60, or 100 mg/kg. Animals were randomized according to
tumor size and drug treatment was started when the mean tumor size was 150–200 mm3. (A) PANC-1 pancreatic tumor cell line. (B) OVCAR-8 ovarian tumor cell line. (C) PD analysis
of AKT phosphorylation and FASN expression by Western blot. Tumors were harvested 6 h after the last dose. TVB-3166 plasma and tumor drug concentrations were determined by
mass spectrometry. The in-life phase for both studies was performed at Crown Biosciences (Santa Clara, CA; Beijing, China).
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Fig. 7. TVB-3166 inhibits growth of patient-derived non-small-cell lung cancer xenograft tumors: (A) CTG-0165, (B) CTG-0160 and (C) CTG-0743. TVB-3166was dosed once daily by oral
gavage at 60mg/kg. Animals were randomized according to tumor size and drug treatmentwas startedwhen themean tumor size was 150–200mm3. The in-life phase for all studies was
performed at Champions, Oncology (Baltimore, MD).
821R. Ventura et al. / EBioMedicine 2 (2015) 808–824and expression levels of the β-catenin protein. Phosphorylation at S675
is associatedwithβ-catenin stability and nuclear localization (Zhu et al.,
2012). Therefore, inhibition of phosphorylation at this site is expected toresult in the loss of β-catenin protein expression, and consequently TCF
promoter activity, as observed in our data. The underlying mechanism
of pathway inhibition remains to be fully elucidated; however, it may
822 R. Ventura et al. / EBioMedicine 2 (2015) 808–824depend on the palmitoylation of Wnt, a modiﬁcation requisite for the
activity of this protein (Clevers and Nusse, 2012; Fiorentino et al.,
2008). Lipid raft disruption may also contribute to inhibition of
frizzled-LRP6 activation. Together our data show that FASN activity is
required forWnt–β-catenin pathway activity and expression of vital on-
cogenic proteins such as c-Myc, and suggests that tumors driven by β-
catenin and c-Myc activity may be susceptible to treatment by FASN
inhibition.
In agreement with the effects on the PI3K–AKT–mTOR and Wnt–β-
catenin signal transduction pathways, global gene expression analyses
revealed that FASN inhibition modulates many biological processes
important for tumor cell proliferation and survival. In response to
FASN inhibitor treatment, highly similar gene expression changes are
observed in PANC-1 and 22Rv1 tumor cells, indicating FASN inhibition
can affect tumor cells from different tissues and with different genetic
backgrounds similarly. Modulated pathways include lipid, sterol and
glucose metabolism, DNA replication and repair, cell cycle progression,
cell proliferation and survival, and apoptosis. Remarkably, highly con-
certed changes in expression of numerous genes within several path-
ways are observed, showing that the related biological processes are
strongly affected and, further, that master regulators of pathway activity
are likely impacted by FASN inhibition. SREBP regulation of the lipid and
sterol biosynthesis pathways provides a clear example of this in our data.
These gene expression data are guiding further elucidation of FASN inhi-
bition mechanisms of action and the discovery of biomarkers for selec-
tion of tumors types most likely to respond to FASN targeted therapy.
TVB-3166 is a potent and selective FASN inhibitor that shows in vitro
and in vivo activity in diverse preclinical tumor models. Our data show
that once-daily, oral dosing of TVB-3166 is well tolerated and inhibits
growth of patient-derived and cell-line-derived xenograft tumors.
Previous studies by others using FASN inhibitors such as polyphenolic
compounds including G28UCM, orlistat and analogs of C75 have dem-
onstrated in vivo xenograft tumor growth inhibition with limited toxic-
ity (Kridel, 2004; Puig et al., 2009, 2011). Our studies advance these
ﬁndings by characterizing the activity of reversible FASN inhibition on
many diverse tumor types using a highly selective FASN inhibitor thatFig. 8. FASN inhibition blocks metabolic and signal transduction pathways vital to cancer cell g
phorylation in the AKT–mTOR signal transduction pathway. In theWnt–β-catenin pathway, FA
expression of TCF promoter-driven genes such as c-Myc. FASN inhibition impairs the plasma m
Ras. Our data ﬁt a model whereby the disruption of lipid rafts and mislocalization of membrane
pathways such as AKT–mTOR andWnt–β-catenin. Signal transduction through molecules such
glucose and glutamine as well as lipid biosynthesis.does not cause activation of fatty-acid oxidation or other undesirable
effects through off-target activities. In vivo TVB-3166 exposure with
once-daily dosing inhibits FASN approximately 10–12 h each day. This
is in contrast to continuous inhibition in our in vitro studies, and
shows that continuous target engagement is not required for in vivo
tumor growth inhibition. Xenograft tumor growth inhibition was ob-
served in diverse tumormodels representing lung, ovarian, and pancre-
atic tumors with varied molecular genetic features, including KRAS,
ERBB2, c-MET, and PTEN mutations. The OVCAR-8 tumor cell line har-
bors an activating mutation in ERBB2, and in these xenograft tumors
TVB-3166 displayed dose-dependent inhibition of tumor growth. Acti-
vation of receptor tyrosine kinases such as EFGFR, ERBB2, and c-MET
can promote over-expression of FASN and other genes involved in
lipid and sterol biosynthesis, and this may sensitize these types of
tumors to FASN inhibition.
TVB-3166 inhibits tumor growth in patient-derived non-small cell
lung xenograft tumors with both mutant and wild type KRAS mutation
status, as well as with adenocarcinoma and squamous cell carcinoma
histology. Both in vitro and in vivo data suggest that FASN inhibition
may be effective in K-Ras-mutant non-small-cell lung tumors. KRAS
mutations are prevalent in other tumor types such as colorectal and
pancreatic adenocarcinomas. Our data shows that TVB-3166 also in-
hibits growth of the KRAS-mutant PANC-1 xenograft tumor. Mutations
in KRAS have been linked to altered metabolic features of tumor cells,
including pancreatic adenocarcinomas where KRAS mutations are
found in more than 95% of all tumors (Donahue et al., 2012; Jones
et al., 2008; Yachida et al., 2010; Ying et al., 2012). Mutant K-Ras has
been shown to reprogram tumor cell metabolism and cause increased
dependency on glutamine and glucose metabolism (Son et al., 2013).
A consequence of this altered metabolic state is the increased produc-
tion of pyruvate. Pyruvate can be metabolized to lactate to generate
ATP and acetyl-CoA or, alternatively, can be shunted to citrate and
then acetyl-CoA, which is a substrate for palmitate biosynthesis by
FASN (Fig. 8). Thus, mutant K-Ras may increase the dependency of
tumor cells on de novo lipogenesis and provide a biological basis for
targeting these tumors, or a subset of them, with a FASN inhibitor.rowth, proliferation, and survival. FASN inhibition results in inhibition of Akt and S6 phos-
SN inhibition results in the inhibition of Lrp6 and β-catenin phosphorylation as well as the
embrane localization of palmitoylated and other lipid-raft-associated proteins such as N-
-associated proteins can drive inhibition of signaling through cellular growth and survival
as K-Ras or pathways such as AKT–mTOR is tightly linked with tumor cell metabolism of
823R. Ventura et al. / EBioMedicine 2 (2015) 808–824In conclusion, our data show FASN inhibition inhibits xenograft
tumor growth in K-Ras-mutant and wild-type tumor models as well
as tumors from multiple different diseases with mutations in other
commonlymutated or over-expressed oncogenes. Mechanism of action
studies demonstrated that TVB-3166 rapidly shuts down de novo pal-
mitate synthesis, which later results in a range of different outcomes
in tumor cells. Following the depletion of palmitate, gene expression
in tumor cells is altered on a global scale, lipid raft architecture is
disrupted, signaling pathways are inhibited and ultimately the tumor
cell dies through an apoptotic mechanism. Oncogenic signal transduc-
tion pathways including PI3K–AKT–mTOR and β-catenin are inhibited
and importantly, FASN inhibition signiﬁcantly decreases c-Myc expres-
sion and induces apoptosis of c-Myc expressing tumor models. In vivo
activity inWnt–β-catenin-activated and c-Myc over-expressing tumors
models is under investigation. Taken together, thewide range of cellular
mechanistic consequences of FASN inhibition provides potential for
effective treatment of a large number of cancers of unmet need.
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